292 results on '"Varettoni, M."'
Search Results
2. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
3. SARS-CoV-2 Infection in Patients with Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study
4. The possible role of burden of therapy on the risk of myeloma extramedullary spread
5. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
6. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report
7. P1256: A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY
8. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
9. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
10. Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement
11. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement
12. The Impact of Advanced Age According to IPSSWM Cut-Off on the Outcome of Symptomatic and Asymptomatic Waldenström's Macroglobulinemia at Diagnosis
13. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
14. Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
15. UPDATED RESULTS OF THE ASPEN TRIAL FROM A COHORT OF PATIENTS WITH MYD88 WILD-TYPE (MYD88(WT)) WALDENSTROM MACROGLOBULINEMIA (WM)
16. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY
17. Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy
18. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
19. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
20. Consensus statement on the management of waldenström macroglobulinemia patients during the COVID-19 pandemic
21. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
22. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma
23. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies
24. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders
25. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone
26. Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant
27. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies
28. Risk of second cancers in Waldenström macroglobulinemia
29. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases
30. A revised international prognostic score system for Waldenström’s macroglobulinemia
31. PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)
32. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls
33. Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal
34. Flexural erythematous eruption following autologous peripheral blood stem cell transplantation: a study of four cases
35. IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY
36. PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)
37. PF392 MONOCLONAL GAMMOPATHY AND HYPOGAMMAGLOBULINEMIA AS INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE
38. PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY
39. A revised international prognostic score system for Waldenström’s macroglobulinemia
40. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
41. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
42. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
43. The possible role of burden of therapy on the risk of myeloma extramedullary spread
44. 1005O - A revised international prognostic score system for Waldenström’s macroglobulinemia
45. Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry
46. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection
47. Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas
48. Report of Consensus Panel 3 from the 11thInternational Workshop on Waldenström's Macroglobulinemia: Recommendations for Molecular Diagnosis in Waldenström's Macroglobulinemia
49. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma
50. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.